Litcius/Paper detail

Linker-Improved Chimeric Endolysin Selectively Kills Staphylococcus aureus <i>In Vitro</i> , on Reconstituted Human Epidermis, and in a Murine Model of Skin Infection

Fritz Eichenseher, Bjorn L. Herpers, Paul Badoux, Juan Manuel Leyva-Castillo, Raif S. Geha, Mathijs van der Zwart, James McKellar, Ferdinand W. Janssen, Bob de Rooij, Lavanja Selvakumar, Christian Röhrig, Johan Frieling, Mark Offerhaus, Martin J. Loessner, Mathias Schmelcher

2022Antimicrobial Agents and Chemotherapy53 citationsDOIOpen Access PDF

Abstract

activity assays. When surface-attached mixed staphylococcal cultures were exposed to XZ.700 in a simplified microbiome model, the enzyme selectively removed S. aureus and retained S. epidermidis. Furthermore, XZ.700 did not induce resistance in S. aureus during repeated rounds of exposure to sublethal concentrations. Finally, we demonstrated that XZ.700 formulated as a cream is effective at killing S. aureus on reconstituted human epidermis and that an XZ.700-containing gel significantly reduces bacterial numbers compared to an untreated control in a mouse model of S. aureus-induced skin infection.

Topics & Concepts

Staphylococcus aureusMicrobiologyLysinAtopic dermatitisSkin infectionIn vitroBiologyStaphylococcal Skin InfectionsEpidermis (zoology)StaphylococcusHuman skinImmunologyBacteriaEscherichia coliBacteriophageBiochemistryGeneAnatomyGeneticsAntimicrobial Peptides and ActivitiesImmune Response and InflammationDermatology and Skin Diseases
Linker-Improved Chimeric Endolysin Selectively Kills Staphylococcus aureus <i>In Vitro</i> , on Reconstituted Human Epidermis, and in a Murine Model of Skin Infection | Litcius